论文部分内容阅读
目的:探讨二甲双胍格列吡嗪复合制剂治疗2型糖尿病的疗效和安全性。方法:选取2013年9月-2014年9月广东省汕头市龙湖区下蓬医院收治的52例患者,随机分为观察组和对照组,每组各26例,对照组给予口服0.5 g二甲双胍,3次/d;观察组给予0.5 g二甲双胍,5 mg格列吡嗪,口服3次/d。治疗3个月后评价两组患者的临床疗效和安全性。结果:治疗后,观察组患者空腹血糖(FPG)以及餐后2 h血糖(2h PG)、糖化血红蛋白(GHb A1C)均明显低于对照组(P<0.05),两组患者均未产生严重不良反应。结论:二甲双胍格列吡嗪复合制剂治疗2型糖尿病患者,疗效确切,安全性高。
Objective: To investigate the efficacy and safety of metformin glipizide in the treatment of type 2 diabetes mellitus. Methods: From September 2013 to September 2014, 52 patients admitted to XiaPeng Hospital, Longhu District, Shantou City, Guangdong Province were randomly divided into observation group and control group, with 26 cases in each group. The control group was given oral metformin 0.5 g, 3 times / d; the observation group was given 0.5 g metformin, 5 mg glipizide, orally 3 times / d. After 3 months of treatment, the clinical efficacy and safety of the two groups were evaluated. Results: After treatment, fasting blood glucose (FPG), postprandial 2h PG and GHb A1C in observation group were significantly lower than those in control group (P <0.05), and no serious adverse reactions occurred in both groups reaction. Conclusion: Metformin glipizide is effective and safe in patients with type 2 diabetes mellitus.